Supplemental Table S1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Key Points

• The study assesses dose reduction strategies to optimize treatment for metastatic solid tumors, enhancing patient safety and efficacy.
• Key findings are based on dosing schedules that indicate potential adjustments for better outcomes in participants receiving zilovertamab vedotin.
• The research employs a phase 2 design to evaluate the impact of dosage on therapeutic effectiveness in metastatic solid tumor cases.
• These insights may guide future dosing approaches in clinical settings, helping to tailor treatments for individuals with advanced cancers.